Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035

1 INTRODUCTION 34 1.1 STUDY OBJECTIVES 34 1.2 MARKET DEFINITION 34 1.3 STUDY SCOPE 35 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35 1.3.2 INCLUSIONS & EXCLUSIONS 36 1.3.3 YEARS CONSIDERED 36 1.3.4 CURRENCY CONSIDERED 36 1.4 STAKEHOLDERS 37 1.5 SUMMARY OF CHANGES 37 2 RESEARCH METHODOLOGY 39 2.1 RESEARCH DATA 39 2.1.1 SECONDARY DATA 40 2.1.1.1 Objectives of secondary research 40 2.1.1.2 Key data from secondary sources 41 2.1.2 PRIMARY DATA 41 2.1.2.1 Breakdown of primaries 42 2.1.2.2 Key objective of primary research 42 2.2 MARKET ESTIMATION 43 2.2.1 GLOBAL MARKET ESTIMATION 43 2.2.1.1 Company revenue analysis (bottom-up approach) 43 2.2.1.1.1 Revenue share analysis of Sandoz Group AG 44 2.2.1.2 MnM repository analysis 45 2.2.1.3 Primary interviews 45 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 46 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 46 2.3 MARKET GROWTH RATE PROJECTIONS 47 2.4 DATA TRIANGULATION 50 2.5 STUDY ASSUMPTIONS 51 2.6 RESEARCH LIMITATIONS 51 2.7 RISK ANALYSIS 52 3 EXECUTIVE SUMMARY 53 4 PREMIUM INSIGHTS 57 4.1 BIOSIMILARS MARKET OVERVIEW 57 4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY 58 4.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59 4.4 BIOSIMILARS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2035 (USD MILLION) 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Rising global demand for affordable alternatives to expensive biologic therapies 61 5.2.1.2 Increasing number of biosimilar launches and approvals 62 5.2.1.3 Impending and ongoing patent expiry of blockbuster biologics 65 5.2.1.4 Entry of emerging players with cost-efficient manufacturing capabilities 66 5.2.2 RESTRAINTS 67 5.2.2.1 Manufacturing complexities and high cost of biosimilars 67 5.2.2.2 Intense competition and pricing pressure among market players 67 5.2.3 OPPORTUNITIES 68 5.2.3.1 Launch of GLP-1 biosimilars 68 5.2.3.2 Increasing strategic partnerships and collaborations among biosimilar manufacturers 68 5.2.3.3 Growing focus on advanced R&D operating models 69 5.2.4 CHALLENGES 69 5.2.4.1 Increased market competition between biosimilar manufacturers and originator biologic companies 69 5.3 TECHNOLOGY ANALYSIS 70 5.3.1 KEY TECHNOLOGIES 70 5.3.1.1 Advanced bioprocessing & manufacturing technologies 70 5.3.1.2 Analytical & characterization techniques 70 5.3.2 COMPLEMENTARY TECHNOLOGIES 71 5.3.2.1 AI & ML 71 5.3.2.2 Lab automation & robotics 71 5.3.3 ADJACENT TECHNOLOGIES 71 5.3.3.1 Microbial fermentation 71 5.3.3.2 3D bioprinting & high-density cell culture 72 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72 5.5 VALUE CHAIN ANALYSIS 74 5.6 ECOSYSTEM ANALYSIS 75 5.6.1 ROLE IN ECOSYSTEM 76 5.7 PATENT ANALYSIS 77 5.7.1 LIST OF KEY PATENTS 78 5.8 PIPELINE ANALYSIS 80 5.8.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE 80 5.8.2 LIST OF KEY BIOLOGICS TO GO OFF-PATENT 83 5.9 REGULATORY ANALYSIS 84 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 5.9.2 REGULATORY FRAMEWORK 86 5.10 REIMBURSEMENT SCENARIO ANALYSIS 88 5.11 PRICING ANALYSIS 91 5.11.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2022–2024 91 5.11.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2022–2024 93 5.12 KEY CONFERENCES & EVENTS, 2025–2026 95 5.13 PORTER’S FIVE FORCES ANALYSIS 96 5.13.1 THREAT OF NEW ENTRANTS 97 5.13.2 THREAT OF SUBSTITUTES 97 5.13.3 BARGAINING POWER OF SUPPLIERS 97 5.13.4 BARGAINING POWER OF BUYERS 97 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 98 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 98 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 98 5.14.2 KEY BUYING CRITERIA 99 5.15 INVESTMENT & FUNDING SCENARIO 101 5.16 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET 102 5.17 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET 103 5.17.1 INTRODUCTION 103 5.17.2 KEY TARIFF RATES 103 5.17.3 PRICE IMPACT ANALYSIS 104 5.17.4 IMPACT ON COUNTRY/REGION 105 5.17.4.1 North America 105 5.17.4.1.1 US 105 5.17.4.2 Europe 105 5.17.4.3 Asia Pacific 106 5.17.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES 106 6 BIOSIMILARS MARKET, BY DRUG CLASS 107 6.1 INTRODUCTION 108 6.2 MONOCLONAL ANTIBODIES 109 6.2.1 RITUXIMAB 112 6.2.1.1 Rising incidences of autoimmune diseases and cancer to boost segment growth 112 6.2.2 INFLIXIMAB 115 6.2.2.1 Loss of patent exclusivity to fuel adoption for treating autoimmune diseases 115   6.2.3 ADALIMUMAB 118 6.2.3.1 Cost-effectiveness and improved patient access to support segment growth 118 6.2.4 TRASTUZUMAB 121 6.2.4.1 Rising incidence of breast cancer to spur market growth 121 6.2.5 PEMBROLIZUMAB 124 6.2.5.1 Expansion of immunotherapy in oncology to propel segment growth 124 6.2.6 DUPILUMAB 126 6.2.6.1 High cost of originator therapy and ongoing label expansions to increase demand for affordable biosimilars 126 6.2.7 USTEKINUMAB 129 6.2.7.1 High annual treatment costs of original drug to augment segment growth 129 6.2.8 RISANKIZUMAB 132 6.2.8.1 Increased biologic-naïve patient growth and high demand for targeted immunotherapies to fuel adoption 132 6.2.9 OTHER MONOCLONAL ANTIBODIES 135 6.3 GRANULOCYTE COLONY-STIMULATING FACTOR 138 6.3.1 RISING GLOBAL CANCER BURDEN AND INCREASING INVESTMENTS BY PHARMA COMPANIES TO PROPEL MARKET GROWTH 138 6.4 INSULIN 142 6.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH 142 6.5 ERYTHROPOIETIN 145 6.5.1 RISING INCIDENCE OF BLOOD DISEASES TO AUGMENT MARKET GROWTH 145 6.6 RECOMBINANT HUMAN GROWTH HORMONE 149 6.6.1 RISING INCIDENCE OF CACHEXIA AND LIVER DISEASES TO FUEL MARKET GROWTH 149 6.7 ETANERCEPT 152 6.7.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS 152 6.8 FOLLITROPIN 154 6.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TO SPUR MARKET GROWTH 154 6.9 TERIPARATIDE 157 6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST MARKET DEMAND 157 6.10 INTERFERONS 160 6.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 160 6.11 ANTICOAGULANTS 163 6.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH 163 6.12 AFLIBERCEPT 166 6.12.1 HIGH COST OF ORIGINATOR DRUG AND INCREASED PREVALENCE OF AGE-RELATED EYE DISEASES TO DRIVE SEGMENT 166   6.13 GLP-1 ANTAGONIST 169 6.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH 169 6.14 OTHER DRUG CLASSES 172 7 BIOSIMILARS MARKET, BY INDICATION 176 7.1 INTRODUCTION 177 7.2 ONCOLOGY 177 7.2.1 HIGH PREVALENCE OF CANCER TO DRIVE MARKET 177 7.3 INFLAMMATORY & AUTOIMMUNE DISEASES 181 7.3.1 RISING LIFE EXPECTANCY AND GROWING GERIATRIC POPULATION TO AUGMENT MARKET GROWTH 181 7.4 CHRONIC DISEASES 184 7.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO FUEL UPTAKE OF BIOSIMILARS 184 7.5 BLOOD DISORDERS 187 7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND 187 7.6 GROWTH HORMONE DEFICIENCY 190 7.6.1 INCREASING CASES OF GROWTH HORMONE DEFICIENCY AMONG ADULTS TO INCREASE DEMAND FOR BIOSIMILARS 190 7.7 INFECTIOUS DISEASES 193 7.7.1 HIGH POPULATION DENSITY AND INDUSTRIALIZATION OF FOOD PRODUCTION TO DRIVE PREVALENCE IN EMERGING ECONOMIES 193 7.8 TYPE II DIABETES 196 7.8.1 COST-EFFECTIVENESS AND HIGH EFFICACY TO DRIVE BIOSIMILAR ADOPTION FOR DIABETES 196 7.9 OBESITY 199 7.9.1 INCREASING SEDENTARY LIFESTYLE AMONG ADULTS TO PROPEL MARKET GROWTH 199 7.10 OTHER INDICATIONS 202 8 BIOSIMILARS MARKET, BY REGION 206 8.1 INTRODUCTION 207 8.2 EUROPE 207 8.2.1 MACROECONOMIC OUTLOOK FOR EUROPE 208 8.2.2 GERMANY 213 8.2.2.1 Acceptance of biosimilars by physicians over originator products to propel market growth 213 8.2.3 UK 216 8.2.3.1 Rising prevalence of life-threatening diseases to fuel demand for low-priced biosimilars 216 8.2.4 FRANCE 219 8.2.4.1 Increased government R&D investments for biosimilar drugs to augment market growth 219   8.2.5 ITALY 222 8.2.5.1 Favorable government regulations and reimbursement policies to propel market growth 222 8.2.6 SPAIN 225 8.2.6.1 Favorable patient incentives and high healthcare R&D expenditure to promote biosimilar use 225 8.2.7 REST OF EUROPE 228 8.3 ASIA PACIFIC 231 8.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 231 8.3.2 JAPAN 235 8.3.2.1 High demand for affordable biologics and recent patent expiries of blockbuster biologics to drive market 235 8.3.3 CHINA 238 8.3.3.1 Increasing investments in pharmaceutical R&D and innovation to augment market growth 238 8.3.4 INDIA 241 8.3.4.1 Need for government healthcare expenditure reduction to propel adoption of biosimilars 241 8.3.5 SOUTH KOREA 244 8.3.5.1 Favourable government incentives to promote biosimilar use in clinical practice 244 8.3.6 AUSTRALIA 247 8.3.6.1 Launch of biosimilar-switching programs in healthcare settings to aid market adoption 247 8.3.7 REST OF ASIA PACIFIC 250 8.4 NORTH AMERICA 253 8.4.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 253 8.4.2 US 258 8.4.2.1 US to dominate North American biosimilars market during forecast period 258 8.4.3 CANADA 262 8.4.3.1 Favorable government initiatives to drive growth in biopharma research and manufacturing facilities 262 8.5 LATIN AMERICA 265 8.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 265 8.5.2 BRAZIL 269 8.5.2.1 Increased government pharmaceutical R&D investments for biosimilars to aid market growth 269 8.5.3 MEXICO 272 8.5.3.1 Well-developed regulatory landscape and high demand for chronic disease treatment to fuel biosimilar uptake 272 8.5.4 REST OF LATIN AMERICA 275   8.6 MIDDLE EAST 277 8.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 277 8.6.2 GCC COUNTRIES 281 8.6.2.1 Focus on local pharmaceutical R&D to augment market growth 281 8.6.3 REST OF MIDDLE EAST 283 8.7 AFRICA 285 8.7.1 INCREASED CANCER BURDEN AND NEED FOR AFFORDABLE ALTERNATIVES TO HIGH-COST BIOLOGICS TO BOOST ADOPTION 285 8.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 285 9 COMPETITIVE LANDSCAPE 288 9.1 INTRODUCTION 288 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 288 9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2022−2024 288 9.3 REVENUE ANALYSIS, 2020–2024 290 9.4 MARKET SHARE ANALYSIS, 2024 291 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 293 9.5.1 STARS 293 9.5.2 EMERGING LEADERS 293 9.5.3 PERVASIVE PLAYERS 293 9.5.4 PARTICIPANTS 293 9.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024 295 9.5.5.1 Company footprint 295 9.5.5.2 Region footprint 296 9.5.5.3 Drug class footprint 297 9.5.5.4 Indication footprint 298 9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 299 9.6.1 PROGRESSIVE COMPANIES 299 9.6.2 RESPONSIVE COMPANIES 299 9.6.3 DYNAMIC COMPANIES 299 9.6.4 STARTING BLOCKS 299 9.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 301 9.6.5.1 Detailed list of key startups/SMEs 301 9.6.5.2 Competitive benchmarking of key startups/SMEs 302 9.7 COMPANY VALUATION & FINANCIAL METRICS 303 9.7.1 FINANCIAL METRICS 303 9.7.2 COMPANY VALUATION 303 9.8 BRAND/PRODUCT COMPARISON 304 9.9 COMPETITIVE SCENARIO 305 9.9.1 PRODUCT LAUNCHES AND APPROVALS 305 9.9.2 DEALS 306 9.9.3 EXPANSIONS 306 10 COMPANY PROFILES 308 10.1 KEY PLAYERS 308 10.1.1 SANDOZ GROUP AG 308 10.1.1.1 Business overview 308 10.1.1.2 Products offered 309 10.1.1.3 Recent developments 310 10.1.1.3.1 Product launches and approvals 310 10.1.1.3.2 Deals 311 10.1.1.3.3 Expansions 311 10.1.1.3.4 Other developments 312 10.1.1.4 MnM view 312 10.1.1.4.1 Key strengths 312 10.1.1.4.2 Strategic choices 312 10.1.1.4.3 Weaknesses & competitive threats 312 10.1.2 PFIZER INC. 313 10.1.2.1 Business overview 313 10.1.2.2 Products offered 314 10.1.2.3 Recent developments 315 10.1.2.3.1 Product approvals 315 10.1.2.3.2 Deals 316 10.1.2.4 MnM view 316 10.1.2.4.1 Key strengths 316 10.1.2.4.2 Strategic choices 316 10.1.2.4.3 Weaknesses & competitive threats 317 10.1.3 AMGEN INC. 318 10.1.3.1 Business overview 318 10.1.3.2 Products offered 319 10.1.3.3 Products in pipeline 320 10.1.3.4 Recent developments 320 10.1.3.4.1 Product launches and approvals 320 10.1.3.4.2 Deals 321 10.1.3.4.3 Expansions 321 10.1.3.5 MnM view 321 10.1.3.5.1 Key strengths 321 10.1.3.5.2 Strategic choices 322 10.1.3.5.3 Weaknesses & competitive threats 322 10.1.4 CELLTRION INC. 323 10.1.4.1 Business overview 323 10.1.4.2 Products offered 324 10.1.4.3 Recent developments 325 10.1.4.3.1 Product launches and approvals 325 10.1.4.3.2 Deals 326 10.1.4.4 MnM view 326 10.1.4.4.1 Key strengths 326 10.1.4.4.2 Strategic choices 327 10.1.4.4.3 Weaknesses & competitive threats 327 10.1.5 BIOCON 328 10.1.5.1 Business overview 328 10.1.5.2 Products offered 329 10.1.5.3 Recent developments 331 10.1.5.3.1 Product approvals 331 10.1.5.3.2 Deals 331 10.1.5.3.3 Other developments 332 10.1.5.4 MnM view 332 10.1.5.4.1 Key strengths 332 10.1.5.4.2 Strategic choices 332 10.1.5.4.3 Weaknesses & competitive threats 332 10.1.6 DR. REDDY’S LABORATORIES LTD. 333 10.1.6.1 Business overview 333 10.1.6.2 Products offered 334 10.1.6.3 Recent developments 335 10.1.6.3.1 Product launches 335 10.1.6.3.2 Deals 335 10.1.6.3.3 Other developments 336 10.1.7 ELI LILLY AND COMPANY 337 10.1.7.1 Business overview 337 10.1.7.2 Products offered 338 10.1.7.3 Recent developments 339 10.1.7.3.1 Product launches 339 10.1.7.3.2 Deals 339 10.1.7.3.3 Expansions 339 10.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD. 340 10.1.8.1 Business overview 340 10.1.8.2 Products offered 341 10.1.8.3 Recent developments 341 10.1.8.3.1 Product launches and approvals 341 10.1.8.3.2 Deals 342 10.1.8.3.3 Other developments 342 10.1.9 FRESENIUS KABI AG 343 10.1.9.1 Business overview 343 10.1.9.2 Products offered 344 10.1.9.3 Recent developments 345 10.1.9.3.1 Product launches and approvals 345 10.1.9.3.2 Deals 346 10.1.10 STADA ARZNEIMITTEL AG 347 10.1.10.1 Business overview 347 10.1.10.2 Products offered 348 10.1.10.3 Recent developments 349 10.1.10.3.1 Product launches 349 10.1.10.3.2 Deals 349 10.1.10.3.3 Expansions 350 10.1.10.3.4 Other developments 350 10.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 351 10.1.11.1 Business overview 351 10.1.11.2 Products offered 352 10.1.11.3 Recent developments 353 10.1.11.3.1 Product approvals 353 10.1.11.3.2 Deals 353 10.1.11.3.3 Expansions 353 10.1.12 SAMSUNG BIOLOGICS 354 10.1.12.1 Business overview 354 10.1.12.2 Products offered 355 10.1.12.3 Recent developments 357 10.1.12.3.1 Product approvals 357 10.1.12.3.2 Deals 358 10.1.12.3.3 Expansions 358 10.1.13 AMNEAL PHARMACEUTICALS LLC 359 10.1.13.1 Business overview 359 10.1.13.2 Products offered 360 10.1.13.3 Recent developments 360 10.1.13.3.1 Product approvals 360 10.1.13.3.2 Deals 360 10.1.13.3.3 Other developments 361 10.1.14 COHERUS BIOSCIENCES 362 10.1.14.1 Business overview 362 10.1.14.2 Products offered 363 10.1.14.3 Recent developments 363 10.1.14.3.1 Deals 363 10.1.14.3.2 Other developments 363 10.1.15 BIO THERA SOLUTIONS 364 10.1.15.1 Business overview 364 10.1.15.2 Products offered 365 10.1.15.3 Recent developments 365 10.1.15.3.1 Product approvals 365 10.1.15.3.2 Deals 366   10.1.16 APROGEN 367 10.1.16.1 Business overview 367 10.1.16.2 Products offered 367 10.1.16.3 Recent developments 367 10.1.16.3.1 Product approvals 367 10.1.16.4 Products in pipeline 368 10.1.17 SHANGHAI HENLINUS BIOTECH, INC. 369 10.1.17.1 Business overview 369 10.1.17.2 Products offered 370 10.1.17.3 Products in pipeline 370 10.1.17.4 Recent developments 370 10.1.17.4.1 Product approvals 370 10.1.17.4.2 Deals 371 10.1.17.4.3 Other developments 371 10.2 OTHER PLAYERS 372 10.2.1 ALVOTECH 372 10.2.2 AMEGA BIOTECH 373 10.2.3 BIOCAD 374 10.2.4 PROBIOMED S.A. DE C.V. 375 10.2.5 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 375 10.2.6 POLPHARMA BIOLOGICS GROUP 376 10.2.7 NEUCLONE 377 10.2.8 XENTRIA 378 10.2.9 YL BIOLOGICS 379 10.2.10 KASHIV BIOSCIENCES, LLC 380 10.2.11 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC 381 10.2.12 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD. 382 10.2.13 CURATEQ BIOLOGICS PVT. LTD. 383 11 APPENDIX 384 11.1 DISCUSSION GUIDE 384 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 388 11.3 CUSTOMIZATION OPTIONS 390 11.4 RELATED REPORTS 390 11.5 AUTHOR DETAILS 391

TABLE 1 BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS 36 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 48 TABLE 3 BIOSIMILARS MARKET: RISK ANALYSIS 52 TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61 TABLE 5 LIST OF KEY BIOSIMILARS APPROVED BY MAJOR PLAYERS, 2023–2025 63 TABLE 6 LIST OF IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035 65 TABLE 7 COMPARISON AMONG DIFFERENT DRUG TYPES, INVESTMENTS, APPROVAL TIMES, AND NUMBER OF PATIENTS IN STUDIES 67 TABLE 8 BIOSIMILARS MARKET: ROLE IN ECOSYSTEM 76 TABLE 9 BIOSIMILARS MARKET: NUMBER OF PATENTS FILED (APPLIED/GRANTED), 2014–2024 77 TABLE 10 BIOSIMILARS MARKET: INDICATIVE LIST OF KEY PATENTS, 2024 78 TABLE 11 BIOSIMILARS MARKET: PRODUCTS IN CLINICAL PIPELINE 80 TABLE 12 BIOSIMILARS MARKET: LIST OF KEY BIOLOGICS TO GO OFF-PATENT, 2025–2035 83 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 17 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REGULATORY FRAMEWORK 86 TABLE 18 US: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED BIOSIMILARS, 2024–2025 89 TABLE 19 US: REIMBURSEMENT CODES FOR BIOSIMILAR PRODUCTS 90 TABLE 20 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 92 TABLE 21 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2022–2024 (USD) 93 TABLE 22 BIOSIMILARS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 95 TABLE 23 BIOSIMILARS MARKET: PORTER’S FIVE FORCES 97 TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS (%) 98 TABLE 25 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER 100 TABLE 26 US ADJUSTED RECIPROCAL TARIFF RATES 103 TABLE 27 BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 108 TABLE 28 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 109 TABLE 29 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2035 (USD MILLION) 110 TABLE 30 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2035 (USD MILLION) 110 TABLE 31 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 32 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 33 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2035 (USD MILLION) 112 TABLE 34 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2035 (USD MILLION) 112 TABLE 35 RITUXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 113 TABLE 36 NORTH AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 113 TABLE 37 EUROPE: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 114 TABLE 38 ASIA PACIFIC: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 114 TABLE 39 LATIN AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 115 TABLE 40 MIDDLE EAST: RITUXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 115 TABLE 41 INFLIXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 116 TABLE 42 NORTH AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 116 TABLE 43 EUROPE: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 116 TABLE 44 ASIA PACIFIC: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 45 LATIN AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 46 MIDDLE EAST: INFLIXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 117 TABLE 47 ADALIMUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 118 TABLE 48 NORTH AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 119 TABLE 49 EUROPE: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 119 TABLE 50 ASIA PACIFIC: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 51 LATIN AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 52 MIDDLE EAST: ADALIMUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 120 TABLE 53 TRASTUZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 121 TABLE 54 NORTH AMERICA: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 122 TABLE 55 EUROPE: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 122 TABLE 56 ASIA PACIFIC: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 123 TABLE 57 LATIN AMERICA: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 123 TABLE 58 MIDDLE EAST: TRASTUZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 123 TABLE 59 PEMBROLIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 124 TABLE 60 NORTH AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 124 TABLE 61 EUROPE: PEMBROLIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 125 TABLE 62 ASIA PACIFIC: PEMBROLIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 125 TABLE 63 LATIN AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 126 TABLE 64 MIDDLE EAST: PEMBROLIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 126 TABLE 65 DUPILUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 127 TABLE 66 NORTH AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 67 EUROPE: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 68 ASIA PACIFIC: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 69 LATIN AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 129 TABLE 70 MIDDLE EAST: DUPILUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 129 TABLE 71 USTEKINUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 130 TABLE 72 NORTH AMERICA: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 130 TABLE 73 EUROPE: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 74 ASIA PACIFIC: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 75 LATIN AMERICA: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 132 TABLE 76 MIDDLE EAST: USTEKINUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 132 TABLE 77 RISANKIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 133 TABLE 78 NORTH AMERICA: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 79 EUROPE: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 80 ASIA PACIFIC: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 81 LATIN AMERICA: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 82 MIDDLE EAST: RISANKIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 134 TABLE 83 OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2035 (USD MILLION) 136 TABLE 84 NORTH AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 136 TABLE 85 EUROPE: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 137 TABLE 86 ASIA PACIFIC: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 137 TABLE 87 LATIN AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 138 TABLE 88 MIDDLE EAST: OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2035 (USD MILLION) 138 TABLE 89 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY- STIMULATING FACTOR (G-CSF) 139 TABLE 90 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2023–2035 (USD MILLION) 140 TABLE 91 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 140 TABLE 92 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 141 TABLE 93 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 141 TABLE 94 LATIN AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 142 TABLE 95 MIDDLE EAST: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2023–2035 (USD MILLION) 142 TABLE 96 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2023–2035 (USD MILLION) 143 TABLE 97 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2023–2035 (USD MILLION) 143 TABLE 98 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2023–2035 (USD MILLION) 144 TABLE 99 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2023–2035 (USD MILLION) 144 TABLE 100 LATIN AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2023–2035 (USD MILLION) 145 TABLE 101 MIDDLE EAST: BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2023–2035 (USD MILLION) 145 TABLE 102 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 146 TABLE 103 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2023–2035 (USD MILLION) 146 TABLE 104 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 147 TABLE 105 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 147 TABLE 106 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 148 TABLE 107 LATIN AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 148 TABLE 108 MIDDLE EAST: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2023–2035 (USD MILLION) 148 TABLE 109 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2023–2035 (USD MILLION) 149 TABLE 110 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 150 TABLE 111 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 150 TABLE 112 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 113 LATIN AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 114 MIDDLE EAST: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2023–2035 (USD MILLION) 151 TABLE 115 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2023–2035 (USD MILLION) 152 TABLE 116 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 152 TABLE 117 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 153 TABLE 118 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 153 TABLE 119 LATIN AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 154 TABLE 120 MIDDLE EAST: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2023–2035 (USD MILLION) 154 TABLE 121 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2023–2035 (USD MILLION) 155 TABLE 122 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2023–2035 (USD MILLION) 155 TABLE 123 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2023–2035 (USD MILLION) 156 TABLE 124 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2023–2035 (USD MILLION) 156 TABLE 125 LATIN AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2023–2035 (USD MILLION) 157 TABLE 126 MIDDLE EAST: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2023–2035 (USD MILLION) 157 TABLE 127 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2023–2035 (USD MILLION) 158 TABLE 128 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2023–2035 (USD MILLION) 158 TABLE 129 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2023–2035 (USD MILLION) 159 TABLE 130 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2023–2035 (USD MILLION) 159 TABLE 131 LATIN AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2023–2035 (USD MILLION) 160 TABLE 132 MIDDLE EAST: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2023–2035 (USD MILLION) 160 TABLE 133 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2023–2035 (USD MILLION) 161 TABLE 134 NORTH AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2023–2035 (USD MILLION) 161 TABLE 135 EUROPE: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2023–2035 (USD MILLION) 162 TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2023–2035 (USD MILLION) 162 TABLE 137 LATIN AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2023–2035 (USD MILLION) 163 TABLE 138 MIDDLE EAST: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2023–2035 (USD MILLION) 163 TABLE 139 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 2023–2035 (USD MILLION) 164 TABLE 140 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 164 TABLE 141 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 165 TABLE 142 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 165 TABLE 143 LATIN AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 166 TABLE 144 MIDDLE EAST: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 2023–2035 (USD MILLION) 166 TABLE 145 BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2035 (USD MILLION) 167 TABLE 146 NORTH AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 167 TABLE 147 EUROPE: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 168 TABLE 148 ASIA PACIFIC: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 168 TABLE 149 LATIN AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2035 (USD MILLION) 169 TABLE 150 MIDDLE EAST: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2035 (USD MILLION) 169 TABLE 151 BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION, 2023–2035 (USD MILLION) 170 TABLE 152 NORTH AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 170 TABLE 153 EUROPE: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 171 TABLE 154 ASIA PACIFIC: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 171 TABLE 155 LATIN AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 172 TABLE 156 MIDDLE EAST: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION, 2023–2035 (USD MILLION) 172 TABLE 157 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2023–2035 (USD MILLION) 173 TABLE 158 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 173 TABLE 159 EUROPE: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 174 TABLE 160 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 174 TABLE 161 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 175 TABLE 162 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2023–2035 (USD MILLION) 175 TABLE 163 BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 177 TABLE 164 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 178 TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 179 TABLE 166 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 179 TABLE 167 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 180 TABLE 168 LATIN AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2035 (USD MILLION) 180 TABLE 169 MIDDLE EAST: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 181 TABLE 170 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2023–2035 (USD MILLION) 182 TABLE 171 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 182 TABLE 172 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 183 TABLE 173 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 183 TABLE 174 LATIN AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 184 TABLE 175 MIDDLE EAST: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2023–2035 (USD MILLION) 184 TABLE 176 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2023–2035 (USD MILLION) 185 TABLE 177 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 185 TABLE 178 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 186 TABLE 179 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 186 TABLE 180 LATIN AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 187 TABLE 181 MIDDLE EAST: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2023–2035 (USD MILLION) 187 TABLE 182 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2023–2035 (USD MILLION) 188 TABLE 183 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 188 TABLE 184 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 189 TABLE 185 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 189 TABLE 186 LATIN AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 190 TABLE 187 MIDDLE EAST: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2023–2035 (USD MILLION) 190 TABLE 188 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2023–2035 (USD MILLION) 191 TABLE 189 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2035 (USD MILLION) 191 TABLE 190 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2035 (USD MILLION) 192 TABLE 191 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2035 (USD MILLION) 192 TABLE 192 LATIN AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2035 (USD MILLION) 193 TABLE 193 MIDDLE EAST: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2023–2035 (USD MILLION) 193 TABLE 194 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2035 (USD MILLION) 194 TABLE 195 NORTH AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 194 TABLE 196 EUROPE: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 195 TABLE 197 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 195 TABLE 198 LATIN AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 196 TABLE 199 MIDDLE EAST: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2035 (USD MILLION) 196 TABLE 200 BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION, 2023–2035 (USD MILLION) 197 TABLE 201 NORTH AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 197 TABLE 202 EUROPE: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 198 TABLE 203 ASIA PACIFIC: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 198 TABLE 204 LATIN AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 199 TABLE 205 MIDDLE EAST: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION, 2023–2035 (USD MILLION) 199 TABLE 206 BIOSIMILARS MARKET FOR OBESITY, BY REGION, 2023–2035 (USD MILLION) 200 TABLE 207 NORTH AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 2023–2035 (USD MILLION) 200 TABLE 208 EUROPE: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 2023–2035 (USD MILLION) 201 TABLE 209 ASIA PACIFIC: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 2023–2035 (USD MILLION) 201 TABLE 210 LATIN AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY, 2023–2035 (USD MILLION) 202 TABLE 211 MIDDLE EAST: BIOSIMILARS MARKET FOR OBESITY, BY REGION, 2023–2035 (USD MILLION) 202 TABLE 212 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION) 203 TABLE 213 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 203 TABLE 214 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 204 TABLE 215 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 204 TABLE 216 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 205 TABLE 217 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION) 205 TABLE 218 BIOSIMILARS MARKET, BY REGION, 2023–2035 (USD MILLION) 207 TABLE 219 EUROPE: KEY MACROINDICATORS 208 TABLE 220 EUROPE: LIST OF APPROVED BIOSIMILARS, 2022–2025 210 TABLE 221 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 211 TABLE 222 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 211 TABLE 223 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 212 TABLE 224 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 212 TABLE 225 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 214 TABLE 226 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 215 TABLE 227 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 215 TABLE 228 UK: LIST OF APPROVED BIOSIMILARS, 2022–2025 216 TABLE 229 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 217 TABLE 230 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 218 TABLE 231 UK: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 218 TABLE 232 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 220 TABLE 233 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 221 TABLE 234 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 221 TABLE 235 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 223 TABLE 236 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 224 TABLE 237 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 224 TABLE 238 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 226 TABLE 239 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 227 TABLE 240 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 227 TABLE 241 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 229 TABLE 242 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 230 TABLE 243 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 230 TABLE 244 ASIA PACIFIC: KEY MACROINDICATORS 232 TABLE 245 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 232 TABLE 246 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 233 TABLE 247 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 234 TABLE 248 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 234 TABLE 249 JAPAN: LIST OF APPROVED BIOSIMILARS, 2022–2025 236 TABLE 250 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 236 TABLE 251 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 237 TABLE 252 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 237 TABLE 253 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 239 TABLE 254 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 240 TABLE 255 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2023–2025 (USD MILLION) 240 TABLE 256 INDIA: BIOSIMILARS APPROVED AND MARKETED, 2022–2025 241 TABLE 257 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 242 TABLE 258 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 243 TABLE 259 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 243 TABLE 260 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS, 2022–2025 244 TABLE 261 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 245 TABLE 262 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 246 TABLE 263 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 246 TABLE 264 AUSTRALIA: LIST OF APPROVED BIOSIMILARS, 2022–2025 247 TABLE 265 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 248 TABLE 266 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 249 TABLE 267 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 249 TABLE 268 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS, 2022–2025 250 TABLE 269 MALAYSIA: LIST OF APPROVED BIOSIMILARS, 2022–2025 250 TABLE 270 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 251 TABLE 271 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 252 TABLE 272 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 252 TABLE 273 NORTH AMERICA: KEY MACROINDICATORS 254 TABLE 274 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 255 TABLE 275 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 256 TABLE 276 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 257 TABLE 277 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 257 TABLE 278 US: LIST OF APPROVED BIOSIMILARS, 2022–2025 258 TABLE 279 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 260 TABLE 280 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 261 TABLE 281 US: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 261 TABLE 282 CANADA: LIST OF APPROVED BIOSIMILARS, 2022–2025 262 TABLE 283 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 263 TABLE 284 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 264 TABLE 285 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 264 TABLE 286 LATIN AMERICA: KEY MACROINDICATORS 266 TABLE 287 LATIN AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 266 TABLE 288 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 267 TABLE 289 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 268 TABLE 290 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 268 TABLE 291 BRAZIL: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 270 TABLE 292 BRAZIL: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 271 TABLE 293 BRAZIL: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 271 TABLE 294 MEXICO: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 273 TABLE 295 MEXICO: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 274 TABLE 296 MEXICO: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 274 TABLE 297 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 275 TABLE 298 REST OF LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 276 TABLE 299 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 276 TABLE 300 MIDDLE EAST: KEY MACROINDICATORS 278 TABLE 301 MIDDLE EAST: BIOSIMILARS MARKET, BY REGION, 2023–2035 (USD MILLION) 278 TABLE 302 MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 279 TABLE 303 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 280 TABLE 304 MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 280 TABLE 305 GCC COUNTRIES: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 281 TABLE 306 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 282 TABLE 307 GCC COUNTRIES: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 282 TABLE 308 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 283 TABLE 309 REST OF MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 284 TABLE 310 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 284 TABLE 311 AFRICA: KEY MACROINDICATORS 286 TABLE 312 AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 286 TABLE 313 AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 287 TABLE 314 AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 287 TABLE 315 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2022–2024 288 TABLE 316 BIOSIMILARS MARKET: DEGREE OF COMPETITION 292 TABLE 317 BIOSIMILARS MARKET: REGION FOOTPRINT 296 TABLE 318 BIOSIMILARS MARKET: DRUG CLASS FOOTPRINT 297 TABLE 319 BIOSIMILARS MARKET: INDICATION FOOTPRINT 298 TABLE 320 BIOSIMILARS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 301 TABLE 321 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, 2024 302 TABLE 322 BIOSIMILARS MARKET: PRODUCT APPROVALS AND LAUNCHES, JANUARY 2022–APRIL 2025 305 TABLE 323 BIOSIMILARS MARKET: DEALS, JANUARY 2022–APRIL 2025 306 TABLE 324 BIOSIMILARS MARKET: EXPANSIONS, JANUARY 2022– APRIL 2025 306 TABLE 325 SANDOZ GROUP AG: COMPANY OVERVIEW 308 TABLE 326 SANDOZ GROUP AG: PRODUCTS OFFERED 309 TABLE 327 SANDOZ GROUP AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 310 TABLE 328 SANDOZ GROUP AG: DEALS, JANUARY 2022–APRIL 2025 311 TABLE 329 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022–APRIL 2025 311 TABLE 330 SANDOZ GROUP AG: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 312 TABLE 331 PFIZER INC.: COMPANY OVERVIEW 313 TABLE 332 PFIZER INC.: PRODUCTS OFFERED 314 TABLE 333 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 315 TABLE 334 PFIZER INC.: DEALS, JANUARY 2022–APRIL 2025 316 TABLE 335 AMGEN INC.: COMPANY OVERVIEW 318 TABLE 336 AMGEN INC.: PRODUCTS OFFERED 319 TABLE 337 AMGEN INC.: PRODUCTS IN PIPELINE 320 TABLE 338 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 320 TABLE 339 AMGEN INC.: DEALS, JANUARY 2022–APRIL 2025 321 TABLE 340 AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 321 TABLE 341 CELLTRION INC.: COMPANY OVERVIEW 323 TABLE 342 CELLTRION INC.: PRODUCTS OFFERED 324 TABLE 343 CELLTRION INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 325 TABLE 344 CELLTRION INC.: DEALS, JANUARY 2022–APRIL 2025 326 TABLE 345 BIOCON: COMPANY OVERVIEW 328 TABLE 346 BIOCON: PRODUCTS OFFERED 329 TABLE 347 BIOCON: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 331 TABLE 348 BIOCON: DEALS, JANUARY 2022–APRIL 2025 331 TABLE 349 BIOCON: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 332 TABLE 350 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 333 TABLE 351 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 334 TABLE 352 DR. REDDY’S LABORATORIES LTD.: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 335 TABLE 353 DR. REDDY’S LABORATORIES LTD.: DEALS, JANUARY 2022–APRIL 2025 335 TABLE 354 DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 336 TABLE 355 ELI LILLY AND COMPANY: COMPANY OVERVIEW 337 TABLE 356 ELI LILLY AND COMPANY: PRODUCTS OFFERED 338 TABLE 357 ELI LILLY AND COMPANY: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 339 TABLE 358 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–APRIL 2025 339 TABLE 359 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2025 339 TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 340 TABLE 361 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 341 TABLE 362 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 341 TABLE 363 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–APRIL 2025 342 TABLE 364 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 342 TABLE 365 FRESENIUS KABI AG: COMPANY OVERVIEW 343 TABLE 366 FRESENIUS KABI AG: PRODUCTS OFFERED 344 TABLE 367 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 345 TABLE 368 FRESENIUS KABI AG: DEALS, JANUARY 2022–APRIL 2025 346 TABLE 369 STADA ARZEIMITTEL AG: COMPANY OVERVIEW 347 TABLE 370 STADA ARZEIMITTEL AG: PRODUCTS OFFERED 348 TABLE 371 STADA ARZEIMITTEL AG: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 349 TABLE 372 STADA ARZEIMITTEL AG: DEALS, JANUARY 2022–APRIL 2025 349 TABLE 373 STADA ARZEIMITTEL AG: EXPANSIONS, JANUARY 2022–APRIL 2025 350 TABLE 374 STADA ARZEIMITTEL AG: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 350 TABLE 375 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 351 TABLE 376 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 352 TABLE 377 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 353 TABLE 378 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–APRIL 2025 353 TABLE 379 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022–APRIL 2025 353 TABLE 380 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 354 TABLE 381 SAMSUNG BIOLOGICS: PRODUCTS OFFERED 355 TABLE 382 SAMSUNG BIOLOGICS: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 357 TABLE 383 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–APRIL 2025 358 TABLE 384 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–APRIL 2025 358 TABLE 385 AMNEAL PHARMACEUTICALS LLC: COMPANY OVERVIEW 359 TABLE 386 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED 360 TABLE 387 AMNEAL PHARMACEUTICALS LLC: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 360 TABLE 388 AMNEAL PHARMACEUTICALS LLC: DEALS, JANUARY 2022–APRIL 2025 360 TABLE 389 AMNEAL PHARMACEUTICALS LLC: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 361 TABLE 390 COHERUS BIOSCIENCES: COMPANY OVERVIEW 362 TABLE 391 COHERUS BIOSCIENCES: PRODUCTS OFFERED 363 TABLE 392 COHERUS BIOSCIENCES: DEALS, JANUARY 2022–APRIL 2025 363 TABLE 393 COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 363 TABLE 394 BIO THERA SOLUTIONS: COMPANY OVERVIEW 364 TABLE 395 BIO THERA SOLUTIONS: PRODUCTS OFFERED 365 TABLE 396 BIO THERA SOLUTIONS: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 365 TABLE 397 BIO THERA SOLUTIONS: DEALS, JANUARY 2022–APRIL 2025 366 TABLE 398 APROGEN: COMPANY OVERVIEW 367 TABLE 399 APROGEN: PRODUCTS OFFERED 367 TABLE 400 APROGEN: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 367 TABLE 401 APROGEN: PRODUCTS IN PIPELINE 368 TABLE 402 SHANGHAI HENLINUS BIOTECH, INC.: COMPANY OVERVIEW 369 TABLE 403 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCTS OFFERED 370 TABLE 404 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCTS IN PIPELINE 370 TABLE 405 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 370 TABLE 406 SHANGHAI HENLINUS BIOTECH, INC.: DEALS, JANUARY 2022–APRIL 2025 371 TABLE 407 SHANGHAI HENLINUS BIOTECH, INC.: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 371 TABLE 408 ALVOTECH: COMPANY OVERVIEW 372 TABLE 409 AMGEGA BIOTECH: COMPANY OVERVIEW 373 TABLE 410 BIOCAD: COMPANY OVERVIEW 374 TABLE 411 PROBIOMED S.A. DE C.V.: COMPANY OVERVIEW 375 TABLE 412 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.: COMPANY OVERVIEW 375 TABLE 413 POLPHARMA BIOLOGICS GROUP: COMPANY OVERVIEW 376 TABLE 414 NEUCLONE: COMPANY OVERVIEW 377 TABLE 415 XENTRIA: COMPANY OVERVIEW 378 TABLE 416 YL BIOLOGICS: COMPANY OVERVIEW 379 TABLE 417 KASHIV BIOSCIENCES, LLC: COMPANY OVERVIEW 380 TABLE 418 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC: COMPANY OVERVIEW 381 TABLE 419 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.: COMPANY OVERVIEW 382 TABLE 420 CURATEQ BIOLOGICS PVT. LTD.: COMPANY OVERVIEW 383 FIGURE 1 BIOSIMILARS MARKET SEGMENTATION & REGIONAL SCOPE 35 FIGURE 2 BIOSIMILARS MARKET: YEARS CONSIDERED 36 FIGURE 3 BIOSIMILARS MARKET: RESEARCH DESIGN 39 FIGURE 4 BIOSIMILARS MARKET: KEY DATA FROM SECONDARY SOURCES 41 FIGURE 5 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 42 FIGURE 6 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 43 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024) 44 FIGURE 8 REVENUE SHARE ANALYSIS OF SANDOZ GROUP AG (2024) 44 FIGURE 9 BIOSIMILARS MARKET SIZE VALIDATION FROM PRIMARY EXPERTS 46 FIGURE 10 BIOSIMILARS MARKET: TOP-DOWN APPROACH 47 FIGURE 11 BIOSIMILARS MARKET: CAGR PROJECTIONS 48 FIGURE 12 BIOSIMILARS MARKET: DATA TRIANGULATION 50 FIGURE 13 BIOSIMILARS MARKET, BY DRUG CLASS, 2025 VS. 2035 (USD MILLION) 53 FIGURE 14 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2025 VS. 2035 (USD MILLION) 54 FIGURE 15 BIOSIMILARS MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION) 55 FIGURE 16 REGIONAL SNAPSHOT OF BIOSIMILARS MARKET 56 FIGURE 17 INCREASING INVESTMENTS IN BIOSIMILAR RESEARCH AND GROWING DEMAND FOR COST-EFFECTIVE TREATMENT OPTIONS TO DRIVE MARKET 57 FIGURE 18 US AND MONOCLONAL ANTIBODIES ARE EXPECTED TO ACCOUNT FOR LARGEST MARKET SHARE IN 2025 58 FIGURE 19 REST OF EUROPE TO REGISTER HIGHEST CAGR FROM 2025 TO 2035 59 FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 59 FIGURE 21 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 22 BIOSIMILARS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73 FIGURE 23 BIOSIMILARS MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 24 BIOSIMILARS MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 25 BIOSIMILARS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024) 78 FIGURE 26 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, 2022–2024 (USD) 93 FIGURE 27 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2022–2024 (USD) 94 FIGURE 28 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS 96 FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS 98 FIGURE 30 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER 99 FIGURE 31 BIOSIMILARS MARKET: INVESTMENT & FUNDING SCENARIO, 2023–2025 101 FIGURE 32 BIOSIMILARS MARKET: IMPACT OF AI/GEN AI 102 FIGURE 33 EUROPE: BIOSIMILARS MARKET SNAPSHOT 209 FIGURE 34 NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT 255 FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMILARS MARKET, 2020–2024 (USD MILLION) 290 FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOSIMILARS MARKET (2024) 291 FIGURE 37 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 294 FIGURE 38 BIOSIMILARS MARKET: COMPANY FOOTPRINT 295 FIGURE 39 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300 FIGURE 40 EV/EBITDA OF KEY VENDORS 303 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 303 FIGURE 42 BIOSIMILARS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 304 FIGURE 43 SANDOZ GROUP AG: COMPANY SNAPSHOT 309 FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT 314 FIGURE 45 AMGEN INC.: COMPANY SNAPSHOT 319 FIGURE 46 CELLTRION INC.: COMPANY SNAPSHOT 324 FIGURE 47 BIOCON: COMPANY SNAPSHOT 329 FIGURE 48 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT 334 FIGURE 49 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 338 FIGURE 50 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 340 FIGURE 51 FRESENIUS KABI AG: COMPANY SNAPSHOT 344 FIGURE 52 STADA ARZEIMITTEL AG: COMPANY SNAPSHOT 348 FIGURE 53 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 352 FIGURE 54 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 355 FIGURE 55 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT 359 FIGURE 56 COHERUS BIOSCIENCES: COMPANY SNAPSHOT 362 FIGURE 57 BIO THERA SOLUTIONS: COMPANY SNAPSHOT 364 FIGURE 58 SHANGHAI HENLINUS BIOTECH, INC.: COMPANY SNAPSHOT 369